Global Biologics Safety Testing

Biologics Safety Testing Comprehensive Study by Type (Endotoxin Tests, Sterility Tests, Cell Line Authentication and Characterization Tests, Bioburden Tests, Cell Line Authentication, Residual Host Contaminant Detection Tests, Adventitious Agent Detection Tests, Others), Application (Vaccine Development, Blood Products Testing, Cellular & Gene Therapy, Tissue and Tissue-Related Products Testing, Stem Cell Research), End Use (Hospitals, Specialty Clinics), Component (Kits & Reagents, Services, Instruments) Players and Region - Global Market Outlook to 2030

Biologics Safety Testing Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Biosafety is an important mechanism that ensures the wellbeing of laboratory workers. Biosafety also includes the remainder of the medical facilities (including other hospital personnel and patients), the population, and research staff and patients. Work with identified and characterised strains of viable microorganisms that are not known to cause disease in healthy adult humans. Nonpathogenic or mildly dangerous agents, such as regularly isolated bacteria and fungi, as well as higher-risk pathogens, such as Mycobacterium tuberculosis and viral hemorrhagic fever agents, can be included in these microorganisms. Various classification schemata have been established to categorise the threats posed by these microorganisms to patients. Biologics Safety Testing provides a wide variety of clinical and industrial substance evaluations. Biologics Safety Testing ensures a product's safety, purity, and potency when adhering to customer manufacturing schedules and streamlining procedures to have industry-leading turnaround times.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledCharles River Laboratories International, Inc (United States), Merck KGaA (Germany), Lonza Group AG (Switzerland), SGS S.A. (Switzerland), Thermo Fisher Scientific Inc (United States), WuXi AppTec (China), Sartorius AG (Germany), Cytovance Biologics, Inc (Hepalink Inc.) (United States), Pace Analytical Services LLC (United States) and Toxikon Corporation (United States)


This growth is primarily driven by Demand for Biopharmaceuticals and Technical Progress in High Throughput Process Development.

Globally, a noticeable market trend is evident Rising Implementation of Quality by Design (QBD) Principles Major Players, such as Charles River Laboratories International, Inc (United States), Merck KGaA (Germany), Lonza Group AG (Switzerland), SGS S.A. (Switzerland), Thermo Fisher Scientific Inc (United States), WuXi AppTec (China), Sartorius AG (Germany), Cytovance Biologics, Inc (Hepalink Inc.) (United States), Pace Analytical Services LLC (United States) and Toxikon Corporation (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Developments in the Market:
On 20th November, 2020 – Ampersand Capital Partners (Leading Private Equity Firm), Signed a Merger Agreement of its Pacific Biomarkers Subsidiary with Neomed-Labs. This Merger is Intended to Establish Phase of Growth for The Now Combined Company and Provide Clinical Laboratory Testing for The Pharma, IVD, And Biotech Markets. and On 30th June, 2020 - Smiths Detection Announced its Agreement to Acquire PathSensors (Leading Bio-Technology Solutions and Environmental-Testing Company), The Acquisition Is Aimed to Expand Smiths Detection’s Sensing Capabilities Across the CBRNE (Chemical, Biological, Radiological, Nuclear and Explosive) Spectrum.
On 31st March, 2020 - Biolidics launched its ten-minute rapid test kits for COVID-19, the Launch is Followed by The Provisional Authorization from Singapore’s HAS. The First Batch of Biolidics’ Rapid Test Kits Is Expected to Be Available in April 2020.

Regulatory Insights:
United States, Code of Federal Regulations Title 21 “Sec. 610.20-610.21, General Biological Products Standards” - Modification of Any Particular Test Method, Manufacturing Process or The Conditions Under Which It Is Conducted as Required in This Part or In the Additional Standards for Specific Biological Products in Parts Is Permitted Only under the Approval Conditions.

Influencing Trend:
Rising Implementation of Quality by Design (QBD) Principles

Market Growth Drivers:
Demand for Biopharmaceuticals and Technical Progress in High Throughput Process Development

Challenges:
Lack of Trained Professionals

Restraints:
High Initial Investments

Opportunities:
Low Penetration in Emerging Regions Particularly Asia and Growing Healthcare Infrastructure

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Biologics Safety Testing Market
- Analysis about New Entrants in Biologics Safety Testing Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Biologics Safety Testing Study Sheds Light on
— The Biologics Safety Testing Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Biologics Safety Testing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Biologics Safety Testing industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Endotoxin Tests
  • Sterility Tests
  • Cell Line Authentication and Characterization Tests
  • Bioburden Tests
  • Cell Line Authentication
  • Residual Host Contaminant Detection Tests
  • Adventitious Agent Detection Tests
  • Others
By Application
  • Vaccine Development
  • Blood Products Testing
  • Cellular & Gene Therapy
  • Tissue and Tissue-Related Products Testing
  • Stem Cell Research
By End Use
  • Hospitals
  • Specialty Clinics

By Component
  • Kits & Reagents
  • Services
  • Instruments

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Demand for Biopharmaceuticals
      • 3.2.2. Technical Progress in High Throughput Process Development
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Rising Implementation of Quality by Design (QBD) Principles
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biologics Safety Testing, by Type, Application, End Use, Component and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Biologics Safety Testing (Value)
      • 5.2.1. Global Biologics Safety Testing by: Type (Value)
        • 5.2.1.1. Endotoxin Tests
        • 5.2.1.2. Sterility Tests
        • 5.2.1.3. Cell Line Authentication and Characterization Tests
        • 5.2.1.4. Bioburden Tests
        • 5.2.1.5. Cell Line Authentication
        • 5.2.1.6. Residual Host Contaminant Detection Tests
        • 5.2.1.7. Adventitious Agent Detection Tests
        • 5.2.1.8. Others
      • 5.2.2. Global Biologics Safety Testing by: Application (Value)
        • 5.2.2.1. Vaccine Development
        • 5.2.2.2. Blood Products Testing
        • 5.2.2.3. Cellular & Gene Therapy
        • 5.2.2.4. Tissue and Tissue-Related Products Testing
        • 5.2.2.5. Stem Cell Research
      • 5.2.3. Global Biologics Safety Testing by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
      • 5.2.4. Global Biologics Safety Testing by: Component (Value)
        • 5.2.4.1. Kits & Reagents
        • 5.2.4.2. Services
        • 5.2.4.3. Instruments
      • 5.2.5. Global Biologics Safety Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Biologics Safety Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Charles River Laboratories International, Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza Group AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. SGS S.A. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. WuXi AppTec (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sartorius AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cytovance Biologics, Inc (Hepalink Inc.) (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pace Analytical Services LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Toxikon Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biologics Safety Testing Sale, by Type, Application, End Use, Component and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Biologics Safety Testing (Value)
      • 7.2.1. Global Biologics Safety Testing by: Type (Value)
        • 7.2.1.1. Endotoxin Tests
        • 7.2.1.2. Sterility Tests
        • 7.2.1.3. Cell Line Authentication and Characterization Tests
        • 7.2.1.4. Bioburden Tests
        • 7.2.1.5. Cell Line Authentication
        • 7.2.1.6. Residual Host Contaminant Detection Tests
        • 7.2.1.7. Adventitious Agent Detection Tests
        • 7.2.1.8. Others
      • 7.2.2. Global Biologics Safety Testing by: Application (Value)
        • 7.2.2.1. Vaccine Development
        • 7.2.2.2. Blood Products Testing
        • 7.2.2.3. Cellular & Gene Therapy
        • 7.2.2.4. Tissue and Tissue-Related Products Testing
        • 7.2.2.5. Stem Cell Research
      • 7.2.3. Global Biologics Safety Testing by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
      • 7.2.4. Global Biologics Safety Testing by: Component (Value)
        • 7.2.4.1. Kits & Reagents
        • 7.2.4.2. Services
        • 7.2.4.3. Instruments
      • 7.2.5. Global Biologics Safety Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biologics Safety Testing: by Type(USD Million)
  • Table 2. Biologics Safety Testing Endotoxin Tests , by Region USD Million (2018-2023)
  • Table 3. Biologics Safety Testing Sterility Tests , by Region USD Million (2018-2023)
  • Table 4. Biologics Safety Testing Cell Line Authentication and Characterization Tests , by Region USD Million (2018-2023)
  • Table 5. Biologics Safety Testing Bioburden Tests , by Region USD Million (2018-2023)
  • Table 6. Biologics Safety Testing Cell Line Authentication , by Region USD Million (2018-2023)
  • Table 7. Biologics Safety Testing Residual Host Contaminant Detection Tests , by Region USD Million (2018-2023)
  • Table 8. Biologics Safety Testing Adventitious Agent Detection Tests , by Region USD Million (2018-2023)
  • Table 9. Biologics Safety Testing Others , by Region USD Million (2018-2023)
  • Table 10. Biologics Safety Testing: by Application(USD Million)
  • Table 11. Biologics Safety Testing Vaccine Development , by Region USD Million (2018-2023)
  • Table 12. Biologics Safety Testing Blood Products Testing , by Region USD Million (2018-2023)
  • Table 13. Biologics Safety Testing Cellular & Gene Therapy , by Region USD Million (2018-2023)
  • Table 14. Biologics Safety Testing Tissue and Tissue-Related Products Testing , by Region USD Million (2018-2023)
  • Table 15. Biologics Safety Testing Stem Cell Research , by Region USD Million (2018-2023)
  • Table 16. Biologics Safety Testing: by End Use(USD Million)
  • Table 17. Biologics Safety Testing Hospitals , by Region USD Million (2018-2023)
  • Table 18. Biologics Safety Testing Specialty Clinics , by Region USD Million (2018-2023)
  • Table 19. Biologics Safety Testing: by Component(USD Million)
  • Table 20. Biologics Safety Testing Kits & Reagents , by Region USD Million (2018-2023)
  • Table 21. Biologics Safety Testing Services , by Region USD Million (2018-2023)
  • Table 22. Biologics Safety Testing Instruments , by Region USD Million (2018-2023)
  • Table 23. South America Biologics Safety Testing, by Country USD Million (2018-2023)
  • Table 24. South America Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 25. South America Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 26. South America Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 27. South America Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 28. Brazil Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 29. Brazil Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 30. Brazil Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 31. Brazil Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 32. Argentina Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 33. Argentina Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 34. Argentina Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 35. Argentina Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 36. Rest of South America Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 37. Rest of South America Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 38. Rest of South America Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 39. Rest of South America Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 40. Asia Pacific Biologics Safety Testing, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 44. Asia Pacific Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 45. China Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 46. China Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 47. China Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 48. China Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 49. Japan Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 50. Japan Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 51. Japan Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 52. Japan Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 53. India Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 54. India Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 55. India Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 56. India Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 57. South Korea Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 58. South Korea Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 59. South Korea Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 60. South Korea Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 61. Taiwan Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 62. Taiwan Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 63. Taiwan Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 64. Taiwan Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 65. Australia Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 66. Australia Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 67. Australia Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 68. Australia Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 73. Europe Biologics Safety Testing, by Country USD Million (2018-2023)
  • Table 74. Europe Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 75. Europe Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 76. Europe Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 77. Europe Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 78. Germany Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 79. Germany Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 80. Germany Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 81. Germany Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 82. France Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 83. France Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 84. France Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 85. France Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 86. Italy Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 87. Italy Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 88. Italy Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 89. Italy Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 90. United Kingdom Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 91. United Kingdom Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 92. United Kingdom Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 93. United Kingdom Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 94. Netherlands Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 95. Netherlands Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 96. Netherlands Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 97. Netherlands Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 98. Rest of Europe Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 99. Rest of Europe Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 100. Rest of Europe Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 101. Rest of Europe Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 102. MEA Biologics Safety Testing, by Country USD Million (2018-2023)
  • Table 103. MEA Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 104. MEA Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 105. MEA Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 106. MEA Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 107. Middle East Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 108. Middle East Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 109. Middle East Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 110. Middle East Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 111. Africa Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 112. Africa Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 113. Africa Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 114. Africa Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 115. North America Biologics Safety Testing, by Country USD Million (2018-2023)
  • Table 116. North America Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 117. North America Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 118. North America Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 119. North America Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 120. United States Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 121. United States Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 122. United States Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 123. United States Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 124. Canada Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 125. Canada Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 126. Canada Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 127. Canada Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 128. Mexico Biologics Safety Testing, by Type USD Million (2018-2023)
  • Table 129. Mexico Biologics Safety Testing, by Application USD Million (2018-2023)
  • Table 130. Mexico Biologics Safety Testing, by End Use USD Million (2018-2023)
  • Table 131. Mexico Biologics Safety Testing, by Component USD Million (2018-2023)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Biologics Safety Testing: by Type(USD Million)
  • Table 143. Biologics Safety Testing Endotoxin Tests , by Region USD Million (2025-2030)
  • Table 144. Biologics Safety Testing Sterility Tests , by Region USD Million (2025-2030)
  • Table 145. Biologics Safety Testing Cell Line Authentication and Characterization Tests , by Region USD Million (2025-2030)
  • Table 146. Biologics Safety Testing Bioburden Tests , by Region USD Million (2025-2030)
  • Table 147. Biologics Safety Testing Cell Line Authentication , by Region USD Million (2025-2030)
  • Table 148. Biologics Safety Testing Residual Host Contaminant Detection Tests , by Region USD Million (2025-2030)
  • Table 149. Biologics Safety Testing Adventitious Agent Detection Tests , by Region USD Million (2025-2030)
  • Table 150. Biologics Safety Testing Others , by Region USD Million (2025-2030)
  • Table 151. Biologics Safety Testing: by Application(USD Million)
  • Table 152. Biologics Safety Testing Vaccine Development , by Region USD Million (2025-2030)
  • Table 153. Biologics Safety Testing Blood Products Testing , by Region USD Million (2025-2030)
  • Table 154. Biologics Safety Testing Cellular & Gene Therapy , by Region USD Million (2025-2030)
  • Table 155. Biologics Safety Testing Tissue and Tissue-Related Products Testing , by Region USD Million (2025-2030)
  • Table 156. Biologics Safety Testing Stem Cell Research , by Region USD Million (2025-2030)
  • Table 157. Biologics Safety Testing: by End Use(USD Million)
  • Table 158. Biologics Safety Testing Hospitals , by Region USD Million (2025-2030)
  • Table 159. Biologics Safety Testing Specialty Clinics , by Region USD Million (2025-2030)
  • Table 160. Biologics Safety Testing: by Component(USD Million)
  • Table 161. Biologics Safety Testing Kits & Reagents , by Region USD Million (2025-2030)
  • Table 162. Biologics Safety Testing Services , by Region USD Million (2025-2030)
  • Table 163. Biologics Safety Testing Instruments , by Region USD Million (2025-2030)
  • Table 164. South America Biologics Safety Testing, by Country USD Million (2025-2030)
  • Table 165. South America Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 166. South America Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 167. South America Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 168. South America Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 169. Brazil Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 170. Brazil Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 171. Brazil Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 172. Brazil Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 173. Argentina Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 174. Argentina Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 175. Argentina Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 176. Argentina Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 177. Rest of South America Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 178. Rest of South America Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 179. Rest of South America Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 180. Rest of South America Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 181. Asia Pacific Biologics Safety Testing, by Country USD Million (2025-2030)
  • Table 182. Asia Pacific Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 183. Asia Pacific Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 184. Asia Pacific Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 185. Asia Pacific Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 186. China Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 187. China Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 188. China Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 189. China Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 190. Japan Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 191. Japan Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 192. Japan Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 193. Japan Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 194. India Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 195. India Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 196. India Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 197. India Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 198. South Korea Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 199. South Korea Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 200. South Korea Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 201. South Korea Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 202. Taiwan Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 203. Taiwan Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 204. Taiwan Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 205. Taiwan Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 206. Australia Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 207. Australia Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 208. Australia Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 209. Australia Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 212. Rest of Asia-Pacific Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 213. Rest of Asia-Pacific Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 214. Europe Biologics Safety Testing, by Country USD Million (2025-2030)
  • Table 215. Europe Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 216. Europe Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 217. Europe Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 218. Europe Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 219. Germany Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 220. Germany Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 221. Germany Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 222. Germany Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 223. France Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 224. France Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 225. France Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 226. France Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 227. Italy Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 228. Italy Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 229. Italy Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 230. Italy Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 231. United Kingdom Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 232. United Kingdom Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 233. United Kingdom Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 234. United Kingdom Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 235. Netherlands Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 236. Netherlands Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 237. Netherlands Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 238. Netherlands Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 239. Rest of Europe Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 240. Rest of Europe Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 241. Rest of Europe Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 242. Rest of Europe Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 243. MEA Biologics Safety Testing, by Country USD Million (2025-2030)
  • Table 244. MEA Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 245. MEA Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 246. MEA Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 247. MEA Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 248. Middle East Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 249. Middle East Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 250. Middle East Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 251. Middle East Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 252. Africa Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 253. Africa Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 254. Africa Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 255. Africa Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 256. North America Biologics Safety Testing, by Country USD Million (2025-2030)
  • Table 257. North America Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 258. North America Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 259. North America Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 260. North America Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 261. United States Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 262. United States Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 263. United States Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 264. United States Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 265. Canada Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 266. Canada Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 267. Canada Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 268. Canada Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 269. Mexico Biologics Safety Testing, by Type USD Million (2025-2030)
  • Table 270. Mexico Biologics Safety Testing, by Application USD Million (2025-2030)
  • Table 271. Mexico Biologics Safety Testing, by End Use USD Million (2025-2030)
  • Table 272. Mexico Biologics Safety Testing, by Component USD Million (2025-2030)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biologics Safety Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Biologics Safety Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Biologics Safety Testing: by End Use USD Million (2018-2023)
  • Figure 7. Global Biologics Safety Testing: by Component USD Million (2018-2023)
  • Figure 8. South America Biologics Safety Testing Share (%), by Country
  • Figure 9. Asia Pacific Biologics Safety Testing Share (%), by Country
  • Figure 10. Europe Biologics Safety Testing Share (%), by Country
  • Figure 11. MEA Biologics Safety Testing Share (%), by Country
  • Figure 12. North America Biologics Safety Testing Share (%), by Country
  • Figure 13. Global Biologics Safety Testing share by Players 2023 (%)
  • Figure 14. Global Biologics Safety Testing share by Players (Top 3) 2023(%)
  • Figure 15. Global Biologics Safety Testing share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Charles River Laboratories International, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Charles River Laboratories International, Inc (United States) Revenue: by Geography 2023
  • Figure 19. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 21. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Lonza Group AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. SGS S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. SGS S.A. (Switzerland) Revenue: by Geography 2023
  • Figure 25. Thermo Fisher Scientific Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Thermo Fisher Scientific Inc (United States) Revenue: by Geography 2023
  • Figure 27. WuXi AppTec (China) Revenue, Net Income and Gross profit
  • Figure 28. WuXi AppTec (China) Revenue: by Geography 2023
  • Figure 29. Sartorius AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Sartorius AG (Germany) Revenue: by Geography 2023
  • Figure 31. Cytovance Biologics, Inc (Hepalink Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cytovance Biologics, Inc (Hepalink Inc.) (United States) Revenue: by Geography 2023
  • Figure 33. Pace Analytical Services LLC (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pace Analytical Services LLC (United States) Revenue: by Geography 2023
  • Figure 35. Toxikon Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Toxikon Corporation (United States) Revenue: by Geography 2023
  • Figure 37. Global Biologics Safety Testing: by Type USD Million (2025-2030)
  • Figure 38. Global Biologics Safety Testing: by Application USD Million (2025-2030)
  • Figure 39. Global Biologics Safety Testing: by End Use USD Million (2025-2030)
  • Figure 40. Global Biologics Safety Testing: by Component USD Million (2025-2030)
  • Figure 41. South America Biologics Safety Testing Share (%), by Country
  • Figure 42. Asia Pacific Biologics Safety Testing Share (%), by Country
  • Figure 43. Europe Biologics Safety Testing Share (%), by Country
  • Figure 44. MEA Biologics Safety Testing Share (%), by Country
  • Figure 45. North America Biologics Safety Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Charles River Laboratories International, Inc (United States)
  • Merck KGaA (Germany)
  • Lonza Group AG (Switzerland)
  • SGS S.A. (Switzerland)
  • Thermo Fisher Scientific Inc (United States)
  • WuXi AppTec (China)
  • Sartorius AG (Germany)
  • Cytovance Biologics, Inc (Hepalink Inc.) (United States)
  • Pace Analytical Services LLC (United States)
  • Toxikon Corporation (United States)
Additional players considered in the study are as follows:
Eurofins Scientific SE (Luxembourg) , Avance Biosciences Inc (United States) , Source Bioscience (United Kingdom)
Select User Access Type

Key Highlights of Report


May 2024 246 Pages 93 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biologics Safety Testing Quantitative research analysis
Global Biologics Safety Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Biologics Safety Testing market are Charles River Laboratories International, Inc (United States), Merck KGaA (Germany), Lonza Group AG (Switzerland), SGS S.A. (Switzerland), Thermo Fisher Scientific Inc (United States), WuXi AppTec (China), Sartorius AG (Germany), Cytovance Biologics, Inc (Hepalink Inc.) (United States), Pace Analytical Services LLC (United States) and Toxikon Corporation (United States), to name a few.
is dominating the Biologics Safety Testing Market.
"Lack of Trained Professionals" is seen as one of the major challenges by many Industry Players of Biologics Safety Testing Market
The Biologics Safety Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Biologics Safety Testing market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Biologics Safety Testing Report?

Have a Query? Click Here

Other Related Reports

Stem Cell Assay Comprehensive Study by Type (Viability/Cytotoxicity, Isolation & Purification, Cell Identification, Proliferation, Differentiation, Function, Apoptosis), Application (Regenerative Med...
$ 3750
Downstream Processing Comprehensive Study by Type (Chromatography Columns and Resins, Filters, Membrane Adsorbers, Single-use Products, Other Products (Consumables and Accessories)), Application (Mon...
$ 3750
Recombinant Protein Drugs Comprehensive Study by Application (Medicine, Research, Biotechnology, Others), Category (Protein, Monoclonal Antibody, Vaccine, Cytokines, Others) Players and Region - Glob...
$ 3500
Metallic Nanoparticles Comprehensive Study by Synthesis Method (Chemical Methods, Physical Methods, Bio-Based Methods), End-Use Industry (Pharmaceutical & Healthcare, Electrical & Electronics, Cataly...
$ 3650
Injectable Drug Delivery Formulation Comprehensive Study by Type (Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations, Long-acting Formulations), Application (Autoimmune Disease...
$ 3450
Competent Cells Comprehensive Study by Type (Cloned Competent Cells, Agrobacterium Tumefaciens Competent Cells, Expression Competent Cells), Application (Cloning {Subcloning & Routine Cloning, Phage ...
$ 3750